Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03

NCT03328234 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT03328234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 3
Overall status
Unknown status
Start date
September 1, 2017
Completion date
December 31, 2022
Enrollment
2 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

imrt with or without concurrent chemotherapy for esophageal cancer